HOUSTON, Nov. 2, 2026 /PRNewswire/ — Contrario Medical, Inc., a Houston-based medical device company developing next-generation sperm separation technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Cyperus. Cyperus is a sterile, single-use device that prepares motile sperm from semen for use in in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI) and intrauterine insemination (IUI).
“FDA clearance of Cyperus is the culmination of a lot of creative and hard work by our talented team,” said Albert Huang, MD, CEO of Contrario Medical. “We built this technology to improve the experience for healthcare providers and for the patients who depend on them in the fertility space.”
Leading clinicians in reproductive medicine advised Contrario Medical as it brought Cyperus to market.